Bionomics Limited (BNOX)

Market Cap	10.27M
Revenue (ttm)	14,998
Net Income (ttm)	-21.09M
Shares Out	10.69M
EPS (ttm)	33.04
PE Ratio	0.03
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,554
Open	0.950
Previous Close	0.930
Day's Range	0.930 - 0.970
52-Week Range	0.840 - 6.410
Beta	-0.09
Analysts	Strong Buy
Price Target	9.00 (+837.5%)
Earnings Date	n/a

About BNOX

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 16, 2021
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: BNOX

Financial Performance

In 2023, Bionomics's revenue was 22,047, a decrease of -91.64% compared to the previous year's 263,634. Losses were -31.85 million, 46.4% more than in 2022.

Financial numbers in AUD

Analyst Forecast

According to 2 analysts, the average rating for BNOX stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 837.50% from the latest price.

Price Target

$9.0

(837.50% upside)

Analyst Consensus: Strong Buy